Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

Summary

Phase 2, open-label study that will evaluate the safety, tolerability, antitumor activities.

Timeline

Start

2018-07-25

Primary completion

2021-01-31

Completion

2021-06-30

Publications

• Lucibello G, Mograbi B, Milano G, Hofman P, Brest P. PD-L1 regulation revisited: impact on immunotherapeutic strategies. Trends Mol Med. 2021 Sep;27(9):868-881. doi: 10.1016/j.molmed.2021.06.005. Epub 2021 Jun 26.

Drugs

Indications